Immuno-oncology and interventional oncology: a winning combination. The latest scientific evidence.
Ablation Techniques
/ methods
Antineoplastic Agents, Immunological
/ administration & dosage
CTLA-4 Antigen
/ antagonists & inhibitors
Clinical Trials as Topic
Humans
Medical Oncology
/ methods
Neoplasms
/ immunology
Programmed Cell Death 1 Receptor
/ antagonists & inhibitors
Progression-Free Survival
Radiology, Interventional
/ methods
Treatment Outcome
Tumor Microenvironment
/ drug effects
Journal
European review for medical and pharmacological sciences
ISSN: 2284-0729
Titre abrégé: Eur Rev Med Pharmacol Sci
Pays: Italy
ID NLM: 9717360
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
entrez:
13
7
2019
pubmed:
13
7
2019
medline:
2
10
2020
Statut:
ppublish
Résumé
Interventional oncology (IO) is an emergent field in interventional radiology that can be considered the fourth pillar of oncology. Interventional oncology has the unique capability to treat malignancy in a loco-regional fashion enabling curative (percutaneous ablation), disease stabilization (intra-arterial chemo/radioembolization), and palliative treatment (such as biliary drainage or nephrostomy). The whole arsenal of IO acts by inducing necrosis and apoptosis, with interactions with the tumour's microenvironment potentially crucial for oncological outcomes. Considering that tumour's microenvironment is a pivotal target for both immuno-oncology and interventional-oncology, the interactions between these two anti-tumour weapons must be investigated to understand their synergy. Interestingly, substantial efforts have been directed to understand which technique combinations are best for specific tumours. This review article summarizes the latest scientific evidence highlighting the future prospective of this winning combination, integrating evidence-reported literature and experience-based perceptions.
Identifiants
pubmed: 31298386
doi: 10.26355/eurrev_201906_18201
pii:
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
CTLA-4 Antigen
0
CTLA4 protein, human
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM